Condition: Small Cell Lung Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated * If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| University of Colorado Anschutz Medical Campus ( Site 1110) | Aurora, Colorado, United States | Recruiting |
| University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111) | Miami, Florida, United States | Recruiting |
| University of Chicago ( Site 1108) | Chicago, Illinois, United States | Recruiting |
| Dana Farber Cancer Institute ( Site 1105) | Boston, Massachusetts, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103) | Hackensack, New Jersey, United States | Recruiting |
| Roswell Park Cancer Institute ( Site 1107) | Buffalo, New York, United States | Recruiting |
| Providence Portland Medical Center ( Site 1101) | Portland, Oregon, United States | Recruiting |
| Sarah Cannon Research Institute ( Site 7001) | Nashville, Tennessee, United States | Recruiting |
| Medical College of Wisconsin ( Site 1112) | Milwaukee, Wisconsin, United States | Recruiting |
| Hospital Universitario Austral ( Site 2204) | Pilar, Buenos Aires, Argentina | Recruiting |
| Sanatorio Parque ( Site 2203) | Rosario, Santa Fe Province, Argentina | Recruiting |
| Princess Alexandra Hospital ( Site 5300) | Woolloongabba, Queensland, Australia | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06780137